Biogen Idec Is Evaluating Strategic Options For Zevalin
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech is considering divesting or partnering the non-Hodgkin’s B-cell lymphoma treatment.
You may also be interested in...
CTI Plans Label Expansion For Zevalin After Acquiring The NHL Drug From Biogen
Cell Therapeutics intends to initiate clinical studies to expand use of the drug into front-line lymphoma settings.
CTI Plans Label Expansion For Zevalin After Acquiring The NHL Drug From Biogen
Cell Therapeutics intends to initiate clinical studies to expand use of the drug into front-line lymphoma settings.
Rituxan Adds Third NHL Indication In 2006
The Genentech/Biogen Idec oncologic, first approved in 1997, is now also approved for first-line with CVP and ongoing treatment of stable disease.